Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Mapping Chemo-Resistance Profiles of Pediatric Acute Leukemia through Integration of Ex-Vivo Drug Screens with Molecular Data

Anna Pia Enblad, Olga Krali, Kristin Blom, Claes Andersson, Britt-Marie Frost, Josefine Palle, Arja Harila, Erik Forestier, Jukka Kanerva, Trond Flægstad, Ólafur G Jónsson, Kjeld Schmiegelow, Mats Heyman, Peter Nygren, Rolf Larsson, Gudmar Lönnerholm, Jessica Nordlund

Blood (2023) 142 (Supplement 1): 1449.

https://doi.org/10.1182/blood-2023-180693

Published: 2023

Journal Articles

Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012

Bernward Zeller, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose Maria Fernandez Navarro, Henrik Hasle, Jahnukainen Kirsi, Kristian Juul-Dam, Gertjan J.L. Kaspers, Zhanna Kovalova, Birgitte Lausen, Monica C. Munthe-Kaas, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Maria Tierens, Jonas Abrahamsson

Blood (2023) 142 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2023-184921

Published: 2023

Journal Articles

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Barbara De Moerloose, Nira Arad-Cohen, Daniel Cheuk, Jose Maria Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Gertjan J.L. Kaspers, Zhanna Kovalova, Birgitte Lausen, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Maria Tierens, Bernward Zeller, Jonas Abrahamsson

Blood (2023) 142 (Supplement 1): 831.

https://doi.org/10.1182/blood-2023-187251

Published: 2023

Journal Articles

The Role of Small Nucleolar RNAs As Putative Biomarkers of Chemoresistance in Pediatric Acute Lymphoblastic Leukemia

Olga Krali, Anna Pia Enblad, Kristin Blom, Claes Andersson, Britt-Marie Frost, Josefine Palle, Arja Harila, Olli Lohi, Erik Forestier, Jukka Kanerva, Trond Flægstad, Ólafur G Jónsson, Kjeld Schmiegelow, Mats Heyman, Peter Nygren, Rolf Larsson, Gudmar Lönnerholm, Jessica Nordlund

Blood (2023) 142 (Supplement 1): 6064.

https://doi.org/10.1182/blood-2023-185687

Published: 2023

Journal Articles

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Henrik Hasle, Ronald M. Kline, Eigil Kjeldsen, Nik F. Nik-Abdul-Rashid, Deepa Bhojwani, Jeffrey M. Verboon, Stephanie P. DiTroia, Katherine R. Chao, Klas Raaschou-Jensen, Josefine Palle, C. Michel Zwaan, Charlotte Guldborg Nyvold, Vijay G. Sankaran, Alan B. Cantor

Blood (2022) 139 (21): 3159–3165.

https://doi.org/10.1182/blood.2021011463

Published: 2022

Includes: Supplemental data

Journal Articles

Genomic and Transcriptomic Characterization of Adult and Pediatric Relapsed Acute Myeloid Leukemia Reveals Novel Therapeutic Targets

Svea Stratmann, Sara A Yones, Jitong Sun, PhD, Aron Skaftason, Markus Mayrhofer, PhD, Nina Norgren, PhD, Morten Krogh Herlin, MD, Anna Eriksson, PhD, Martin Hoglund, MD, Josefine Palle, PhD, Kirsi Jahnukainen, MD PhD, Katja Pokrovskaja Tamm, PhD, Lucia Cavelier, PhD, Linda Holmfeldt, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139427

Published: 2020

Journal Articles

Obesity Is Associated with Favorable Cytogenetic Abnormalities in Pediatric Acute Myeloid Leukemia

Ditte Juel Adolfsen Løhmann, MD, Jonas Abrahamsson, MD PhD, Shau-Yin Ha, MD PhD, Olafur G. Jonsson, MD PhD, Gertjan J.L. Kaspers, MD PhD, Minna M Koskenvuo, MD PhD, Birgitte Lausen, MD PhD, Barbara De Moerloose, MD PhD, Josefine Palle, MD PhD, Bernward Zeller, MD PhD, Henrik Hasle, MD PhD, Lillian Sung, MD PhD

Blood (2017) 130 (Supplement 1): 1302.

https://doi.org/10.1182/blood.V130.Suppl_1.1302.1302

Published: 2017

Journal Articles

Effect of Age and Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia

Ditte Juel Adolfsen Løhmann, MD, Jonas Abrahamson, Shau Yin Ha, Ólafur G. Jónsson, Minna Koskenvuo, Birgitte Lausen, MD, Josefine Palle, Bernward Zeller, Henrik Hasle, MD PhD

Blood (2015) 126 (23): 3745.

https://doi.org/10.1182/blood.V126.23.3745.3745

Published: 2015

Journal Articles

DNA Methylation-Based Subtype Prediction for Pediatric Acute Lymphoblastic Leukemia (ALL)

Blood (2014) 124 (21): 490.

https://doi.org/10.1182/blood.V124.21.490.490

Published: 2014

Journal Articles

Anthracycline Type during Induction Associated with Outcome in Pediatric t(8;21) and Inv(16) AML

Henrik Hasle, Jonas Abrahamsson, MD PhD, Evelina S De Bont, MDPhD, Valerie de Haas, Barbara De Moerloose, Erik Forestier, MD PhD, Shau Yin Ha, Jesper Heldrup, Kirsi Jahnukainen, Ólafur G Jónsson, MD, Birgitte Lausen, MD, Josefine Palle, MD PhD, Ardine Reedijk, MSc, Kadri Saks, MD, Bernward Zeller

Blood (2014) 124 (21): 11.

https://doi.org/10.1182/blood.V124.21.11.11

Published: 2014

Journal Articles

The Applicability Of The WHO Classification In Pediatric AML. A NOPHO-AML Study

Julie Damgaard Sandahl, Eigil Kjeldsen, Jonas Abrahamsson, Shau-Yin Ha, Jesper Heldrup, Kirsi Jahnukainen, Ólafur G Jónsson, Birgitte Lausen, Josefine Palle, Bernward Zeller, Erik Forestier, Henrik Hasle

Blood (2013) 122 (21): 1354.

https://doi.org/10.1182/blood.V122.21.1354.1354

Published: 2013

Journal Articles

Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004

Henrik Hasle, Jonas Abrahamsson, Erik Forestier, Shau-Yin Ha, Jesper Heldrup, Kirsi Jahnukainen, Ólafur Gísli Jónsson, Birgitte Lausen, Josefine Palle, Bernward Zeller

Blood (2012) 120 (5): 978–984.

https://doi.org/10.1182/blood-2012-03-416701

Published: 2012

Includes: Supplemental data

Journal Articles

Response: high ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia

Anna Staffas, Meena Kanduri, Randi Hovland, Richard Rosenquist, Hans Beier Ommen, Jonas Abrahamsson, Erik Forestier, Kirsi Jahnukainen, Ólafur G. Jónsson, Bernward Zeller, Josefine Palle, Gudmar Lönnerholm, Henrik Hasle, Hans Ehrencrona, Lars Palmqvist

Blood (2012) 119 (4): 1087–1088.

https://doi.org/10.1182/blood-2011-12-393355

Published: 2012

Journal Articles

Presence of FLT3 -ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia

Blood (2011) 118 (22): 5905–5913.

https://doi.org/10.1182/blood-2011-05-353185

Published: 2011

Includes: Supplemental data

Journal Articles

Hyperdiploidy in Childhood AML Associated with Low Age and AML-M7. A NOPHO-AML Study and Literature Review,

Julie Damgaard Sandahl, MD, Jonas Abrahamsson, Jesper Heldrup, MD, Kirsi Jahnukainen, Olafur G Jonsson, MD, Birgitte Lausen, Josefine Palle, Bernward Zeller, Erik Forestier, MD, PhD, Eigil Kjeldsen, Henrik Hasle, M.D.

Blood (2011) 118 (21): 3529.

https://doi.org/10.1182/blood.V118.21.3529.3529

Published: 2011

Journal Articles

Gemtuzumab Ozogamicin as Post-Consolidation Therapy Does Not Prevent Relapse In Children with AML. Results of the NOPHO-AML 2004 Study

Henrik Hasle, M.D., Jonas Abrahamsson, Erik Forestier, MD, PhD, Shau-Yin Ha, Jesper Heldrup, MD, Kirsi Jahnukainen, Olafur G Jonsson, MD, Birgitte Lausen, Josefine Palle, Bernward Zeller

Blood (2011) 118 (21): 1534.

https://doi.org/10.1182/blood.V118.21.1534.1534

Published: 2011

Journal Articles

Age and Prognosis in Pediatric AML

Pernille Wendtland Edslev, Jonas Abrahamsson, Niels Clausen, Erik Forestier, Göran Gustafsson, Jesper Heldrup, Liisa Hovi, Kirsi Jahnukainen, Gudmundur Jonmundsson, Josefine Palle, Bem Zeller, Henrik Hasle

Blood (2008) 112 (11): 2990.

https://doi.org/10.1182/blood.V112.11.2990.2990

Published: 2008

Journal Articles

Gemtuzumab Ozagamicin Is Well Tolerated as Post-Consolidation Therapy in Childhood AML.

Henrik Hasle, Jonas Abrahamsson, Niels Clausen, Erik Forestier, Göran Gustafsson, Jesper Heldrup, Liisa Hovi, Kirsi Jahnukainen, Gudmundur Jonmundsson, Josefine Palle, Bernward Zeller

Blood (2007) 110 (11): 4367.

https://doi.org/10.1182/blood.V110.11.4367.4367

Published: 2007

NARROW

Mapping Chemo-Resistance Profiles of Pediatric Acute Leukemia through Integration of Ex-Vivo Drug Screens with Molecular Data

Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

The Role of Small Nucleolar RNAs As Putative Biomarkers of Chemoresistance in Pediatric Acute Lymphoblastic Leukemia

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Genomic and Transcriptomic Characterization of Adult and Pediatric Relapsed Acute Myeloid Leukemia Reveals Novel Therapeutic Targets

Obesity Is Associated with Favorable Cytogenetic Abnormalities in Pediatric Acute Myeloid Leukemia

Effect of Age and Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia

DNA Methylation-Based Subtype Prediction for Pediatric Acute Lymphoblastic Leukemia (ALL)

Anthracycline Type during Induction Associated with Outcome in Pediatric t(8;21) and Inv(16) AML

The Applicability Of The WHO Classification In Pediatric AML. A NOPHO-AML Study

Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004

Response: high ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia

Presence of FLT3 -ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia

Hyperdiploidy in Childhood AML Associated with Low Age and AML-M7. A NOPHO-AML Study and Literature Review,

Gemtuzumab Ozogamicin as Post-Consolidation Therapy Does Not Prevent Relapse In Children with AML. Results of the NOPHO-AML 2004 Study

Age and Prognosis in Pediatric AML

Gemtuzumab Ozagamicin Is Well Tolerated as Post-Consolidation Therapy in Childhood AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only